Payment overview · 2025
General Payments
$8,141.92
21 reported records · 11 companies
Healthcare provider profile · identity verified
Badi Eghterafi, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · HENDERSON, NV · NPI 1427468537
Verified facts
What the public records show
CMS Open Payments records show Badi Eghterafi, D.O. received $8,141.92 in general payments during 2025 across 21 reported records.
PFIZER INC. accounted for 88.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Paxlovid.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $7,198.97 | 88.4% | 6 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $193.26 | 2.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $166.81 | 2.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $152.09 | 1.9% | 3 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $98.32 | 1.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $90.87 | 1.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $86.79 | 1.1% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $74.31 | 0.9% | 1 | 2025 |
| Lucid Diagnostics Inc. | Unresolved — no canonical attribution shown | $47.50 | 0.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.40 | 0.2% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.60 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $6,780.00 | 2 |
| Food and Beverage | $1,361.92 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $6,180.00 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $600.00 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $222.65 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $166.81 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $142.50 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $125.11 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $86.79 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $74.31 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $26.98 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.40 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 11 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
55 | 19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
75 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 577 | 222 |
| Lisinopril | Lisinopril | 273 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 250 | 100 |
| Metformin Hcl | Metformin Hcl | 237 | 87 |
| Gabapentin | Gabapentin | 184 | 80 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 143 | 98 |
| Diclofenac Sodium | Diclofenac Sodium | 140 | 49 |
| Losartan Potassium | Losartan Potassium | 135 | 56 |
| Omeprazole | Omeprazole | 134 | 49 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 114 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 49 |
| Trazodone Hcl | Trazodone Hcl | 105 | 43 |
| Alendronate Sodium | Alendronate Sodium | 96 | 33 |
| Famotidine | Famotidine | 94 | 46 |
| Montelukast Sodium | Montelukast Sodium | 92 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 90 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 80 | 31 |
| Jardiance | Empagliflozin | 75 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 70 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 68 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 66 | 30 |
| Ibuprofen | Ibuprofen | 63 | 53 |
| Carvedilol | Carvedilol | 55 | 23 |
| Farxiga | Dapagliflozin Propanediol | 55 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 55 | 18 |
| Xarelto | Rivaroxaban | 45 | 14 |
| Ozempic | Semaglutide | 39 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | 14 |
| Potassium Chloride | Potassium Chloride | 36 | 15 |
| Sildenafil Citrate | Sildenafil Citrate | 36 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 12 |
| Furosemide | Furosemide | 33 | 16 |
| Buspirone Hcl | Buspirone Hcl | 32 | 13 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 32 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Allopurinol | Allopurinol | 30 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 30 | 12 |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 27 | 12 |
| Repatha Sureclick | Evolocumab | 27 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 27 | 14 |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 26 | 12 |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 25 | 11 |
| Spiriva Respimat | Tiotropium Bromide | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 16 |
| Hydrocortisone | Hydrocortisone | 23 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Azithromycin | Azithromycin | 21 | 19 |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Simvastatin | Simvastatin | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Eliquis | Apixaban | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | 11 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Baclofen | Baclofen | 17 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 16 |
| Amoxicillin | Amoxicillin | 15 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 15 |
| Mupirocin | Mupirocin | 15 | 15 |
| Prednisone | Prednisone | 15 | 15 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | 12 |
| Acyclovir | Acyclovir | 13 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $8,141.92 · 21 records | PFIZER INC. | AIRSUPRA, BREZTRI, ELIQUIS, NURTEC ODT, OTEZLA, PAXLOVID, QUTENZA, The Cologuard Plus Collection Kit, VOQUEZNA, ZAVZPRET, ZORYVE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error